PDF(Pubmed)
Abstract：
Gliomas are highly malignant and invasive tumors lacking clear boundaries. Previous bioinformatics and experimental analyses have indicated that F-box and leucine-rich repeat protein 6 (FBXL6), a protein crucial for the cell cycle and tumorigenesis, is highly expressed in certain types of tumors. The high expression level of FBXL6 is reported to promote tumor growth and adversely affect patient survival. However, the molecular mechanism, prognostic value and drug sensitivity of FBXL6 in glioma remain unclear. To address this, the present study analyzed FBXL6 expression in gliomas, utilizing data from The Cancer Genome Atlas and Chinese Glioma Genome Atlas databases. Analysis of FBXL6 mRNA expression levels, combined with patient factors such as age, sex and tumor grade using Kaplan-Meier plots and nomograms, demonstrated a strong correlation between FBXL6 expression and glioma progression. Co-expression networks provided further insights into the biological function of FBXL6. Additionally, using CIBERSORT and TISDB tools, the correlation between FBXL6 expression correlation tumor-infiltrating immune cells and immune genes was demonstrated to be statistically significant. These findings were validated by examining FBXL6 mRNA and protein levels in glioma tissues using various techniques, including western blot, reverse transcription-quantitative PCR and immunohistochemistry. These assays demonstrated the role of FBXL6 in glioma progression. Furthermore, drug sensitivity analysis demonstrated a strong correlation between FBXL6 expression and various drugs, which indicated that FBXL6 may potentially act as a future promising therapeutic target in glioma treatment. Therefore, the present study identified FBXL6 as a diagnostic and prognostic marker in patients with gliomas and highlighted its potential role in glioma progression.
摘要：
胶质瘤是高度恶性和侵袭性肿瘤，缺乏明确的边界。先前的生物信息学和实验分析表明，F-box和富含亮氨酸的重复蛋白6（FBXL6），一种对细胞周期和肿瘤发生至关重要的蛋白质，在某些类型的肿瘤中高表达。据报道,FBXL6的高表达水平促进肿瘤生长并不利地影响患者存活。然而,分子机制，FBXL6在胶质瘤中的预后价值和药物敏感性尚不清楚。为了解决这个问题，本研究分析了FBXL6在胶质瘤中的表达，利用来自癌症基因组图谱和中国胶质瘤基因组图谱数据库的数据。FBXL6mRNA表达水平分析，结合患者因素，如年龄，使用Kaplan-Meier图和列线图的性别和肿瘤分级，显示FBXL6表达与胶质瘤进展之间有很强的相关性。共表达网络为FBXL6的生物学功能提供了进一步的见解。此外,使用CIBERSORT和TISDB工具，FBXL6表达相关性肿瘤浸润免疫细胞和免疫基因之间的相关性被证明具有统计学意义。这些发现通过使用各种技术检查胶质瘤组织中的FBXL6mRNA和蛋白质水平得到了验证，包括westernblot,逆转录定量PCR和免疫组织化学。这些测定证明了FBXL6在神经胶质瘤进展中的作用。此外，药物敏感性分析表明FBXL6表达与各种药物之间存在很强的相关性，这表明FBXL6可能作为未来神经胶质瘤治疗的有希望的治疗靶点。因此,本研究将FBXL6确定为胶质瘤患者的诊断和预后标志物,并强调了其在胶质瘤进展中的潜在作用.
